Vir Biotechnology
VIR · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$68.6M
Net margin
-638.9%
ROE
-57.2%
Revenue CAGR (2y)
-10.8%
EPS (FY2025)
-3.16
Net profit (FY2025)
$-438.0M
Ask MarketChacha about VIR
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 25, 2026
Vir Biotechnology shares rose ~8% on continued post-Q2 earnings momentum, fueled by the Astellas collaboration's upfront revenue and equity investment that drove a swing to profitability and boosted cash/investments above $1B, alongside optimism around pipeline catalysts including VIR-5500 data.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $68.6M | $-438.0M | -3.16 | -638.9% | -57.2% |
| FY2024 | $74.2M | $-522.0M | -3.83 | -703.4% | -45.4% |
| FY2023 | $86.2M | $-615.1M | -4.59 | -713.7% | -38.7% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $238.9M | $80.1M | 0.47 | 33.5% |
| 2026Q1 | $-29,000 | $-125.7M | -0.85 | — |
| 2025Q3 | $240,000 | $-163.1M | -1.17 | -67975.4% |
| 2025Q2 | $1.2M | $-111.0M | -0.80 | -9139.9% |
| 2025Q1 | $3.0M | $-121.0M | -0.88 | -3989.6% |
| 2024Q3 | $2.4M | $-213.7M | -1.56 | -8979.7% |
| 2024Q2 | $3.1M | $-138.4M | -1.02 | -4500.1% |
| 2024Q1 | $56.4M | $-65.3M | -0.48 | -115.8% |
| 2023Q3 | $2.6M | $-163.4M | -1.22 | -6192.2% |
| 2023Q2 | $3.8M | $-194.8M | -1.45 | -5129.7% |
| 2023Q1 | $63.0M | $-141.0M | -1.06 | -223.9% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/5/2026material
- SEC8/5/2026
- SEC7/24/2026material
- SEC6/10/2026material
- SEC5/28/2026material
- SEC5/7/2026
- SEC5/6/2026material
- SEC4/10/2026material
- SEC3/4/2026material
- SEC3/2/2026material
- SEC2/26/2026material
- SEC2/23/2026
- SEC1/12/2026material
2025
- SEC12/16/2025material
- SEC11/5/2025material
- SEC11/5/2025
- SEC8/6/2025material
- SEC8/6/2025
In the news
- Vir Biotechnology (VIR) Could Be 54% Undervalued After Gilead CollaborationSimply Wall Street · 10/18/2026
- Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?Yahoo Finance · 10/17/2026
- Wall Street Analysts Are Bullish on Top Healthcare PicksThe Globe and Mail · 10/15/2026
- VIR Stock Fundamentals & Key RatiosPluang · 10/15/2026
- Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next?MarketBeat · 10/14/2026
- Vir Biotechnology, Gilead Strike Deal for Novel Tumor TreatmentsBenzinga · 10/14/2026
- Vir Biotechnology (VIR) Slides 4.25% to $10.82 as Support at $10.28 Comes Into Focus - BPI Bear Confirmeddars.gov.et · 10/13/2026
- Vir Biotechnology (NasdaqGS:VIR) Stock PriceSimply Wall Street · 10/13/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.